Selected article for: "log rank test compare and lymph node"
Author: Hu, Aimin; Li, Junyu; Ruan, Shufang; Fan, Ying; Liao, Yuqian
Title: Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients
  • Document date: 2019_4_23
    • ID: 106tex7s_7
    Snippet: Statistical analysis was performed using SPSS version 18.0 (SPSS Inc, Chicago, IL, U.S.A.). The distribution of genotypes in patients with different clinicopathological characteristics was compared by two-sided Pearson's χ 2 tests, odds ratios (ORs) and 95% confidence intervals (CI) were calculated by logistic regression. Disease-free survival (DFS) was calculated from date of diagnosis to date of first locoregional recurrence, first distant met.....
    Document: Statistical analysis was performed using SPSS version 18.0 (SPSS Inc, Chicago, IL, U.S.A.). The distribution of genotypes in patients with different clinicopathological characteristics was compared by two-sided Pearson's χ 2 tests, odds ratios (ORs) and 95% confidence intervals (CI) were calculated by logistic regression. Disease-free survival (DFS) was calculated from date of diagnosis to date of first locoregional recurrence, first distant metastasis, or death from any cause (whichever came first). Overall survival (OS) was calculated from date of diagnosis to date of death from any reason or last follow-up. Kaplan-Meier curves with the log-rank test were applied to estimate and compare 5-year DFS and OS rates of patients with different genotypes. Hazard ratios (HR) of recurrence/metastasis and death with 95% CI were estimated by Cox-regression model. The multivariate analysis was adjusted for age, histological grade, tumor size, lymph node status, and vascular invasion. All statistical tests were two-sided, and P<0.05 was considered significant.

    Search related documents:
    Co phrase search for related documents
    • confidence interval and Cox regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • confidence interval and death date: 1, 2, 3, 4, 5, 6
    • confidence interval and death distant metastasis: 1
    • confidence interval and DFS disease free survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • confidence interval and diagnosis date: 1, 2, 3, 4, 5, 6, 7
    • confidence interval and disease free survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • confidence interval and distant metastasis: 1, 2, 3, 4, 5
    • confidence interval and follow reason: 1, 2
    • Cox regression and death date: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • Cox regression and DFS disease free survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • Cox regression and diagnosis date: 1, 2, 3, 4, 5, 6
    • Cox regression and disease free survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • Cox regression and distant metastasis: 1, 2, 3, 4
    • Cox regression model and death date: 1, 2, 3
    • Cox regression model and DFS disease free survival: 1
    • Cox regression model and disease free survival: 1
    • death date and diagnosis date: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • death distant metastasis and distant metastasis: 1, 2, 3, 4, 5
    • DFS disease free survival and distant metastasis: 1, 2, 3, 4